Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of M923 versus EU-licensed Humira in moderate to severe chronic plaque psoriasis
2015-001751-76Phase 3Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis and psoriasis comparing M923 arm with Humira arm (2 arms). Primary endpoint: PASI 75 response. Started Jul 2015; status: completed.
02
Drugs
adalimumabBAX 2923
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2015-001751-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001751-76.